Using indigenously developed resistant models against cisplatin, paclitaxel and dual drugs in ovarian cancer cells, we showed that upregulated IGF-1R expression is crucial to initiate resistance and an activated AKT later assists in maintenance of resistance19, 20. The gene discussed is AKT1; the disease is ovarian carcinoma.